These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 16673283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
    Besses C, Hernández-Boluda JC, Pérez Encinas M, Raya JM, Hernández-Rivas JM, Jiménez Velasco A, Martínez Lopez J, Vicente V, Burgaleta C, GEMFIN.
    Ann Hematol; 2016 Apr; 95(5):719-32. PubMed ID: 26898207
    [Abstract] [Full Text] [Related]

  • 8. Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
    Wong GC, Lee LH.
    Am J Hematol; 2006 Aug; 81(8):624-6. PubMed ID: 16823822
    [Abstract] [Full Text] [Related]

  • 9. [How should patients with essential thrombocythemia be treated?].
    Ikeda Y.
    Rinsho Ketsueki; 2001 Jun; 42(6):447-51. PubMed ID: 11505520
    [No Abstract] [Full Text] [Related]

  • 10. Practical approach to treating essential thrombocythaemia: case studies.
    Reilly JT.
    Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
    [No Abstract] [Full Text] [Related]

  • 11. Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
    Cazzola M.
    Haematologica; 2004 Feb; 89(2):137-8. PubMed ID: 15003887
    [No Abstract] [Full Text] [Related]

  • 12. Thrombocytosis.
    Schafer AI.
    N Engl J Med; 2004 Mar 18; 350(12):1211-9. PubMed ID: 15028825
    [No Abstract] [Full Text] [Related]

  • 13. Essential thrombocythaemia treatment options: addressing patient-specific needs.
    Birgegård G.
    Eur J Haematol Suppl; 2007 Oct 18; (68):27-31. PubMed ID: 17727563
    [No Abstract] [Full Text] [Related]

  • 14. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 18; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 15. Update on diagnosis and management of essential thrombocythemia.
    Gisslinger H.
    Semin Thromb Hemost; 2006 Jun 18; 32(4 Pt 2):430-6. PubMed ID: 16810619
    [Abstract] [Full Text] [Related]

  • 16. Anagrelide: what was new in 2004 and 2005?
    Petrides PE.
    Semin Thromb Hemost; 2006 Jun 18; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [Abstract] [Full Text] [Related]

  • 17. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE.
    Med Klin (Munich); 2006 Aug 15; 101(8):624-34. PubMed ID: 16896569
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
    Finazzi G, Ruggeri M, Rodeghiero F, Barbui T.
    Blood; 2003 May 01; 101(9):3749. PubMed ID: 12707224
    [No Abstract] [Full Text] [Related]

  • 20. Emerging drugs for essential thrombocythemia.
    Masarova L, Verstovsek S.
    Expert Opin Emerg Drugs; 2019 Jun 01; 24(2):93-105. PubMed ID: 31050912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.